

Medical Policy

Cabenuva (cabotegravir and rilpivirine)	
MEDICAL POLICY NUMBER	MED_Clin_Ops-112
CURRENT VERSION EFFECTIVE DATE	3/1/2023
APPLICABLE PRODUCT AND MARKET	Individual Family Plan: ALL Small Group: ALL Medicare Advantage: ALL

Brand New Day/Central Health Medicare Plan develops policies and makes coverage determinations using credible scientific evidence including but not limited to MCG™ Health Guidelines, the ASAM Criteria™, and other third party sources, such as peer-reviewed medical literature generally recognized by the relevant medical community, physician specialty society recommendations, and expert opinion as relevant to supplement those sources. Brand New Day/Central Health Medicare Plan Medical Policies, MCG™ Guidelines, and the ASAM Criteria™ are not intended to be used without the independent clinical judgment of a qualified health care provider considering the individual circumstances of each member's case. The treating health care providers are solely responsible for diagnosis, treatment, and medical advice. Members may contact Brand New Day/Central Health Medicare Plan Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Brand New Day/ Central Health Medicare Plan policy may contact the Health Plan. Brand New Day/Central Health Medicare Plan policies and practices are compliant with federal and state requirements, including mental health parity laws.

If there is a difference between this policy and the member specific plan document, the member benefit plan document will govern. For Medicare Advantage members, Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), govern. Refer to the CMS website at <http://www.cms.gov> for additional information.

Brand New Day/Central Health Medicare Plan medical policies address technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and do not constitute an offer of coverage nor medical advice. Brand New Day/Central Health Medicare Plan medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Brand New Day/Central Health Medicare Plan does not provide health care services and, therefore, cannot guarantee any results or outcomes. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies are updated based on changes in the evidence and healthcare coding and therefore are subject to change without notice. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). MCG™ and Care Guidelines® are trademarks of MCG Health, LLC (MCG).

PURPOSE

The purpose of this policy is to establish the clinical review criteria that support the determination of medical necessity for Cabenuva (cabotegravir and rilpivirine) therapy.

POLICY

Prior Authorization and Medical Review is required.

Coverage for Cabenuva will be provided for 6 months and may be renewed. Renewals will be provided for 12 months.

- Max Units (per dose and over time):
 - o Cabenuva 600 mg/900 mg kit: 1 kit x 1 fill
 - o Cabenuva 400 mg/600 mg kit: 1 kit every 28 days

Medical Policy

Initial

- A. Patient is 18 years of age or older; **AND**
- B. Patient has a diagnosis of human immunodeficiency virus type 1 (HIV-1) infection; **AND**
- C. Patient is virologically suppressed with HIV-RNA < 50 copies/mL and is on a stable antiretroviral regimen; **AND**
- D. Patient has no history of treatment failure or known or suspected resistance to cabotegravir or rilpivirine; **AND**
- E. Patient has not had a previous hypersensitivity reaction to cabotegravir or rilpivirine; **AND**
- F. Patient will NOT receive concomitant therapy with ANY of the following medications that can result in significant decreases of cabotegravir and/or rilpivirine; **AND**
 - a. Carbamazepine
 - b. Oxcarbazepine
 - c. Phenobarbital
 - d. Phenytoin
 - e. Rifabutin
 - f. Rifampin
 - g. Rifapentine
 - h. Dexamethasone (more than a single-dose treatment)
 - i. St. John's wort
- G. Patient will complete oral cabotegravir and rilpivirine \geq 28 days prior to starting therapy; **AND**
- H. Patient has been counseled to contact their healthcare provider if they plan to miss a scheduled monthly injection visit to coordinate treatment with oral therapy to replace up to 2 consecutive monthly injections.

Renewal

- A. Patient continues to meet initial criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc.; **AND**
- B. Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hypersensitivity reactions, hepatotoxicity, serious post-injection reactions, and unremitting depression, etc.; **AND**
- C. Patient has not experienced virologic failure and has documented adherence to therapy, clinical improvement and/or stabilization.

LIMITATIONS/EXCLUSIONS

- 1. Any indication other than those listed above due to insufficient evidence of therapeutic value

DEFINITIONS

- A. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. Initial U.S. Approval: 2021

Medical Policy

CODING

Applicable NDC Codes	
49702-253-15	CABENUVA 400-mg/600-mg Kit - single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine
49702-240-15	CABENUVA 600-mg/900-mg Kit - single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir, single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirine

Applicable Procedure Code	
J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg

Applicable ICD-10 Codes	
B20	Human immunodeficiency virus (HIV) disease
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status

EVIDENCE BASED REFERENCES

1. Product Information: CABENUVA intramuscular extended-release suspension, cabotegravir intramuscular extended-release suspension, rilpivirine intramuscular extended-release suspension. Viiv Healthcare (per FDA), Research Triangle Park, NC, 2022.

POLICY HISTORY

Original Effective Date	5/24/2022
Revised Date	03/01/2023 – Adopted by MA UMC
P&T Committee Endorsement	5/24/2022
Updated to Brand New Day/Central Health Medicare Plan/Central Health Medicare Plan	01/01/2024